Skip to main content
NVDA+0.21%AAPL-0.23%GOOGL+0.30%MSFT-0.42%AMZN-0.29%TSM+0.17%SPCX-4.21%META+0.03%AVGO+0.73%TSLA-0.15%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU+0.27%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.12%ASMLa-4.20%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.03%ABBV-2.40%1398.HK-1.41%CSCO-0.23%CVX+1.27%COST-0.50%ORCL+4.23%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%PG-0.10%AP2d-8.45%CAT-3.33%UNH-0.20%3988.HK-1.16%1816.HK-25.11%0005.HK-1.09%HSBA.L+0.17%0857.HK+0.29%GE-0.33%PM-1.34%0939.HK-1.63%1288.HK-2.19%MS-1.78%NFLX-0.21%CADCHF+0.61%GBPCHF+0.52%AUDCHF+0.43%GBPTRY+0.41%NZDCHF+0.41%USDCAD-0.39%EURCAD-0.34%CADJPY+0.34%GBPHKD+0.32%GBPUSD+0.30%GBPMXN-0.28%AUDSGD+0.28%USDTRY+0.28%EURCHF+0.27%NZDSGD+0.25%CHFJPY-0.25%GBPJPY+0.24%NZDUSD+0.23%AUDUSD+0.22%EURGBP-0.22%USDCHF+0.21%USDNOK-0.21%NZDCAD-0.20%GBPSGD+0.19%NZDMXN+0.18%USDZAR-0.18%AUDJPY+0.17%AUDCAD-0.17%EURSGD+0.16%USDILS+0.16%NZDJPY+0.16%NOKJPY+0.16%CHFSGD+0.15%USDPLN-0.15%USDSEK-0.15%EURAUD-0.14%CHFNOK-0.12%AUDDKK+0.12%EURNZD-0.12%SGDJPY-0.11%EURNOK-0.11%PLNJPY+0.10%EURHKD+0.10%USDDKK-0.10%GBPAUD+0.09%EURZAR-0.08%GBPCAD-0.08%EURCNH+0.07%GBPNZD+0.07%USDTHB+0.07%EURUSD+0.06%USDSGD+0.06%CHFSEK-0.06%GBPZAR-0.06%EURPLN-0.05%EURSEK-0.05%USDJPY-0.05%USDCOP-0.04%EURJPY+0.02%AUDNZD+0.02%USDCNH-0.02%USDMXN-0.01%EURCZK+0.01%USDHKD+0.01%AUDNOK+0.01%EURDKK0.00%COTTON+0.90%HG1+0.74%S1+0.42%XNGUSD+0.41%UKOIL-0.27%USOIL-0.26%W1-0.25%XAGUSD+0.09%GAGUSD+0.09%C1-0.05%GAUUSD+0.04%XAUUSD+0.04%BTCUSD+2.52%ETHUSD+17.67%USDTUSD+0.02%XRPUSD+11.86%SOLUSD+12.05%TRXUSDT+0.77%ZECUSDT+8.78%DOGEUSD+14.12%XMRUSDT+5.57%LINKUSD+13.42%XLMUSD+0.29%BCHUSDT+5.71%UNIUSD+7.23%LTCUSD+9.66%SUIUSD+3.56%HBARUSDT+0.50%TONUSD+26.15%TAOUSDT+3.92%AAVEUSD+3.69%DOTUSDT+0.06%ICPUSDT+0.56%ONDOUSDT+0.47%WLDUSDT+0.17%ARBUSDT+7.07%JUPUSDT+0.62%ATOMUSDT+1.62%INJUSDT+14.60%STXUSDT+5.78%FETUSDT+3.07%TIAUSDT+9.38%PYTHUSDT-0.53%SEIUSDT+4.57%IMXUSDT+0.63%OPUSDT+21.23%GRTUSDT+3.94%IOTAUSDT+0.81%WIFUSDT+2.70%AXSUSDT-1.66%POLUSDT+2.83%FARTCOINUSDT+1.01%EOSUSDT+2.16%DYDXUSDT+3.68%GALAUSDT-1.87%ORDIUSDT+0.11%RONINUSDT-3.42%NOTUSDT+1.21%NVDA+0.21%AAPL-0.23%GOOGL+0.30%MSFT-0.42%AMZN-0.29%TSM+0.17%SPCX-4.21%META+0.03%AVGO+0.73%TSLA-0.15%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU+0.27%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.12%ASMLa-4.20%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.03%ABBV-2.40%1398.HK-1.41%CSCO-0.23%CVX+1.27%COST-0.50%ORCL+4.23%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%PG-0.10%AP2d-8.45%CAT-3.33%UNH-0.20%3988.HK-1.16%1816.HK-25.11%0005.HK-1.09%HSBA.L+0.17%0857.HK+0.29%GE-0.33%PM-1.34%0939.HK-1.63%1288.HK-2.19%MS-1.78%NFLX-0.21%CADCHF+0.61%GBPCHF+0.52%AUDCHF+0.43%GBPTRY+0.41%NZDCHF+0.41%USDCAD-0.39%EURCAD-0.34%CADJPY+0.34%GBPHKD+0.32%GBPUSD+0.30%GBPMXN-0.28%AUDSGD+0.28%USDTRY+0.28%EURCHF+0.27%NZDSGD+0.25%CHFJPY-0.25%GBPJPY+0.24%NZDUSD+0.23%AUDUSD+0.22%EURGBP-0.22%USDCHF+0.21%USDNOK-0.21%NZDCAD-0.20%GBPSGD+0.19%NZDMXN+0.18%USDZAR-0.18%AUDJPY+0.17%AUDCAD-0.17%EURSGD+0.16%USDILS+0.16%NZDJPY+0.16%NOKJPY+0.16%CHFSGD+0.15%USDPLN-0.15%USDSEK-0.15%EURAUD-0.14%CHFNOK-0.12%AUDDKK+0.12%EURNZD-0.12%SGDJPY-0.11%EURNOK-0.11%PLNJPY+0.10%EURHKD+0.10%USDDKK-0.10%GBPAUD+0.09%EURZAR-0.08%GBPCAD-0.08%EURCNH+0.07%GBPNZD+0.07%USDTHB+0.07%EURUSD+0.06%USDSGD+0.06%CHFSEK-0.06%GBPZAR-0.06%EURPLN-0.05%EURSEK-0.05%USDJPY-0.05%USDCOP-0.04%EURJPY+0.02%AUDNZD+0.02%USDCNH-0.02%USDMXN-0.01%EURCZK+0.01%USDHKD+0.01%AUDNOK+0.01%EURDKK0.00%COTTON+0.90%HG1+0.74%S1+0.42%XNGUSD+0.41%UKOIL-0.27%USOIL-0.26%W1-0.25%XAGUSD+0.09%GAGUSD+0.09%C1-0.05%GAUUSD+0.04%XAUUSD+0.04%BTCUSD+2.52%ETHUSD+17.67%USDTUSD+0.02%XRPUSD+11.86%SOLUSD+12.05%TRXUSDT+0.77%ZECUSDT+8.78%DOGEUSD+14.12%XMRUSDT+5.57%LINKUSD+13.42%XLMUSD+0.29%BCHUSDT+5.71%UNIUSD+7.23%LTCUSD+9.66%SUIUSD+3.56%HBARUSDT+0.50%TONUSD+26.15%TAOUSDT+3.92%AAVEUSD+3.69%DOTUSDT+0.06%ICPUSDT+0.56%ONDOUSDT+0.47%WLDUSDT+0.17%ARBUSDT+7.07%JUPUSDT+0.62%ATOMUSDT+1.62%INJUSDT+14.60%STXUSDT+5.78%FETUSDT+3.07%TIAUSDT+9.38%PYTHUSDT-0.53%SEIUSDT+4.57%IMXUSDT+0.63%OPUSDT+21.23%GRTUSDT+3.94%IOTAUSDT+0.81%WIFUSDT+2.70%AXSUSDT-1.66%POLUSDT+2.83%FARTCOINUSDT+1.01%EOSUSDT+2.16%DYDXUSDT+3.68%GALAUSDT-1.87%ORDIUSDT+0.11%RONINUSDT-3.42%NOTUSDT+1.21%
ET

Enliven Therapeutics, Inc. (ELVN)

NASDAQ • Healthcare

$39.49
-$1.35 (-3.3%)
Market closed

Last close at October 13, 2026 at 20:00 UTC

Open$40.09
Day Range$39.27 - $40.98
Avg. Volume (3M)1.5M
Market Cap$2.8B
52 Week Range
$14.79$62.32
Next EarningsIn 28 daysNov 11, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$105.9M
EPS (TTM)
-$1.64
ROA (TTM)
-11.64%
Current Ratio
64.07

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-14.3%Q1 2026-$0.48
+13.6%Q2 2026-$0.38
-26.6%Q3 2026-$0.49
Next

Nov 11

in 28 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -26.6%

Enliven Therapeutics’ earnings missed expectations in the second fiscal quarter of 2026, with reported August 5, 2026 preliminary results showing EPS of $-0.49 trailed the $-0.39 estimate (-27%) and matched the $-0.49 loss per share a year ago (+0.0% YoY). The company posted a GAAP net loss of roughly $32.5 million, down 28.2% from about $25.3 million a year earlier, alongside a GAAP operating loss of around $37.2 million. Cash burn remained evident, with negative operating cash flow of about $18.5 million for the quarter. For the next period, consensus calls for EPS of $-0.43.

Next report — what to expect

Enliven Therapeutics, Inc. (ELVN) reports next on November 11, 2026. Wall Street’s consensus calls for EPS of -$0.48. The company has beaten EPS in 5 of its 8 most recent quarters, so traders will be watching whether results and commentary align with that recent pattern.

View full earnings history

About Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc. is a NASDAQ-listed Biotechnology company in the healthcare sector that is in the clinical development stage. The company discovers and advances small molecule cancer therapies, giving it the profile of an early-stage drug developer rather than a commercial biopharma business.

Name
Enliven Therapeutics, Inc.
CEO
Richard A. Fair
Website
www.enliventherapeutics.com
Industry
Healthcare
Employees
67

Today's Snapshot

AI-generated

ELVN closed 3.3% below yesterday's close, in line with a weaker sector. Trading was lighter than usual, with volume about two-thirds of its usual level. Wall Street critics questioned Enliven’s trial results, raising concerns about its drug-development prospects.

Trading Volume

Below 10d avg (1.1M)

719.7K

vs S&P 500 Today

Strong Underperformance

-3.29%

Updated: October 13, 2026 at 20:15 UTC

Technical Indicators

2 Buy0 Neutral6 Sell
ELVN is technically weak with price trading beneath nearly all moving averages and the classic pivot, while a high ADX signals a strong directional trend to the downside. Momentum readings are overwhelmingly negative as reflected by a very low RSI in the low-20s and a materially negative MACD, and on-balance volume shows selling pressure. Volatility is relatively elevated with an ATR near $2, reinforcing the downside bias. Technical takeaway: Strong Sell — pronounced negative momentum, heavy volume and strong trend strength align with bearish technical conditions.
All signals
  • EMA (5 indicators)$40.69 - $49.40
    Sell
  • RSI (14)21.28
    Buy
  • Stochastic %K (14, 3, 3)12.85
    Buy
  • MACD Level (12, 26)-3.61
    Sell

Peers & Related Assets

RVMDRevolution Medicines, Inc.
$188.44-2.8%
INCYIncyte Corporation
$108.62-2.5%
EXELExelixis, Inc.
$59.51-0.5%
RLAYRelay Therapeutics, Inc.
$17.36-3.5%
NUVBNuvation Bio Inc.
$4.72-3.7%
SNDXSyndax Pharmaceuticals, Inc.
$13.95-15.7%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.